NASDAQ:IMVT Immunovant Q4 2025 Earnings Results & Report $37.04 +1.33 (+3.72%) Closing price 04:00 PM EasternExtended Trading$37.03 -0.01 (-0.03%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immunovant beat analyst earnings expectations in its Q4 2025 results, released May 29, 2025. The company reported EPS of -$0.64 versus the -$0.72 consensus estimate, while revenue was $160 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMay 29, 2025TimeBefore Market OpensConference Call7:00 AM ET Immunovant EPS ResultsActual EPS-$0.64Consensus EPS -$0.72Beat/MissBeat by +$0.08One Year Ago EPS-$0.52EPS Beat Rate4 of last 8 quartersImmunovant Revenue ResultsActual Revenue$160 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Immunovant Q4 2025 Earnings FAQ Did Immunovant beat earnings estimates for Q4 2025? Immunovant (NASDAQ:IMVT) reported earnings of -$0.64 per share for Q4 2025, beating the consensus estimate of -$0.72. The report was announced on Thursday, May 29, 2025. What was Immunovant's revenue for Q4 2025? Immunovant reported revenue of $160 thousand for Q4 2025. Immunovant Earnings HeadlinesImmunovant (IMVT) Q2 2027 Earnings Call TranscriptNovember 9 at 11:30 PM | finance.yahoo.comImmunovant, Inc. (IMVT) Q2 2027 Earnings Call TranscriptNovember 9 at 6:00 PM | seekingalpha.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 11 at 1:00 AM | Behind the Markets (Ad)Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026November 9 at 1:28 PM | marketscreener.comMS&P 500 Futures Up in Premarket Trading; Immunovant, Roivant Sciences LeadNovember 9 at 8:27 AM | barrons.comImmunovant IMVT-1402 RA Win Shapes a $6.3 Billion Bet on the FDANovember 9 at 8:27 AM | 247wallst.comSee More Immunovant Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email. Email Address About ImmunovantImmunovant (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders. Its medicines are investigational and are not approved for commercial use. Immunovant was launched by Roivant Sciences in 2018 and remains part of the Roivant group. The company is led by President and Chief Executive Officer Peter Salzmann.View Immunovant ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
